Form 4: Haemonetics EVP, Chief Technology Officer Anila Lingamneni Reports Stock Sale

Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reported selling 2,305 shares of common stock at $95 per share on May 6, 2024, under a pre-existing 10b5-1 trading plan.

Summary

• On May 6, 2024, Anila Lingamneni, the EVP and Chief Technology Officer of Haemonetics Corp, sold 2,305 shares of common stock.
• The sale was executed at a price of $95 per share.
• The transaction was conducted under a pre-existing 10b5-1 trading plan established on June 2, 2023, and fully executed as of June 5, 2023.
• Following the transaction, Lingamneni directly owns 12,295 shares of Haemonetics Corp.
• This number includes unvested restricted stock units and 289 shares acquired through the company's Employee Stock Purchase Plan on April 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sale by an executive could be perceived neutrally by shareholders as it was conducted under a pre-existing plan.

Key Dates